Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of clinical pharmacology

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270005279580PMID 16172179
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leukocyte arylsulfatase A activity in patients with alcohol‐related cirrhosis

  2001cited by this paper
• New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

  1999cited by this paper
• Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

  1996cited by this paper
• Crystal structure of catechol O-methyltransferase

  1994cited by this paper
• Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages.

  1994cited by this paper
• Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters.

  1994cited by this paper
• Human liver catechol‐O‐methyltransferase pharmacogenetics

  1990cited by this paper
• Association of elevated sulfatides and sulfotransferase activities with human renal cell carcinoma.

  1989cited by this paper
• Tissue-specific expression of human arylsulfatase-C isozymes and steroid sulfatase.

  1987cited by this paper
• Platelet phenol sulfotransferase and erythrocyte catechol‐O‐methytransferase activities: Correlation with methyldopa metabolism

  1984cited by this paper
• Platelet monoamine oxidase and erythrocyte catechol-o-methyltransferase activity in alcoholism and controlled abstinence.

  1983cited by this paper
• Catechol-O-methyltransferase biochemical genetics: Human lymphocyte enzyme

  1981cited by this paper
• Catechol‐O‐methyltransferase activity: A determinant of levodopa response

  1980cited by this paper
• Thiol S‐methylation in uremia: Erythrocyte enzyme activities and plasma inhibitors

  1980cited by this paper
• Methyl conjugation in uraemia: catechol-O-methyltransferase.

  1980cited by this paper
• Noncompartmental determination of the steady-state volume of distribution.

  1979cited by this paper
• Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity.

  1978cited by this paper
• Inheritance of low erythrocyte catechol-o-methyltransferase activity in man.

  1977cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Catechol-O-methyl transferase: pharmacological aspects and physiological role.

  1975cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• The changes in some hydrolytic enzymes in carbon tetrachloride-induced fatty livers.

  1964cited by this paper

• Gut-liver axis dysregulation in colitis underlies structure-dependent pharmacokinetics of a traditional Chinese medicine.

  2026cites this paper
• Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients

  2024cites this paper
• Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects

  2024cites this paper
• Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

  2022cites this paper
• Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.

  2021cites this paper
• Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis

  2021cites this paper
• Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?

  2020influential citation
• Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization.

  2020cites this paper
• Pharmacokinetics and probability of target attainment of micafungin in normal-weight and 1 morbidly obese adults 2

  2020cites this paper
• Antifungal Therapy: New and Evolving Therapies

  2020cites this paper
• Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study

  2020cites this paper
• Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study

  2020cites this paper
• Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta‐analysis

  2020cites this paper
• Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China.

  2020cites this paper
• Challenges in Antifungal Therapy in Diabetes Mellitus

  2020cites this paper
• Comparative pharmacokinetics of the three echinocandins in ICU patients.

  2020cites this paper
• Pharmacokinetics of Micafungin in Critically Ill Patients

  2019cites this paper
• Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

  2019cites this paper
• Fungal Infections in Immunocompromised Hosts

  2019cites this paper
• Candida auris and multidrug resistance: defining the new normal.

  2019cites this paper
• Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults

  2019cites this paper
• Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis

  2019cites this paper
• Anti-Infective Agents

  2019cites this paper
• Overview of antifungal dosing in invasive candidiasis.

  2018cites this paper
• Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study

  2018cites this paper
• Pre-Existing Liver Disease and Toxicity of Antifungals

  2018cites this paper
• Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

  2018cites this paper
• Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients

  2017influential citation
• Clinical Pharmacokinetics and Pharmacodynamics of Micafungin

  2017cites this paper
• Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study

  2017cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Antifungal PK/PD in the critically Ill

  2017cites this paper
• No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins.

  2017cites this paper
• Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation

  2017cites this paper
• Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

  2017cites this paper
• Antifungal agents and liver toxicity: a complex interaction

  2016cites this paper
• Evaluation of the Treatment of Candiduria at an Academic Medical Center

  2016cites this paper
• Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections.

  2016cites this paper
• Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation

  2016cites this paper
• Formación médica continuada: Infección fúngica invasora Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento

  2016cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• Pharmacokinetic/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations.

  2016cites this paper
• Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.

  2016cites this paper
• [Echinocandins: Applied pharmacology].

  2016cites this paper
• Impact of special patient populations on the pharmacokinetics of echinocandins

  2015influential citation
• Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!

  2015cites this paper
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients

  2015cites this paper
• [Strategies for antifungal treatment failure in intensive care units].

  2015cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Strategien bei Versagen einer antimykotischen Therapie auf Intensivstation

  2015cites this paper
• Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterial and Antifungal Agents in Adult Patients With Thermal Injury: A Review of Current Literature

  2015cites this paper
• Echinocandins: The Expanding Antifungal Armamentarium.

  2015cites this paper
• Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction

  2014influential citation
• Effects of echinocandin preparations on adult rat ventricular cardiomyocytes

  2014cites this paper
• Micafungin: an evidence-based review of its place in therapy

  2014cites this paper
• Cardiac Effects of Echinocandins after Central Venous Administration in Adult Rats

  2014cites this paper
• Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.

  2014cites this paper
• Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

  2014cites this paper
• Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.

  2014cites this paper
• Antimicrobial agents, drug adverse reactions and interactions, and cancer.

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants

  2014cites this paper
• Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects.

  2014cites this paper
• OF PHARMACEUTICS AND NANOTECHNOLOGY Antifungal Pharmacology : A Review

  2014cites this paper
• Pharmacogenomics of Antifungal Agents

  2014cites this paper
• 15 Antifungal Pharmacokinetics

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants Jessica K. RobertsChris StockmannJonathan E. Constance • Justin StiersMichael G. SpigarelliRobert M. Ward •

  2014cites this paper
• Antifungal Pharmacology: A Review.

  2014cites this paper
• Pharmacogenomics of Antifungal Agents

  2014cites this paper
• Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis

  2013cites this paper
• ECHINOCANDINS- A REVIEW

  2013cites this paper
• Recent progress in the chemotherapy of human fungal diseases. Emphasis on 1,3-β-glucan synthase and chitin synthase inhibitors.

  2013cites this paper
• Penetration of micafungin into the burn eschar in patients with severe burns

  2013cites this paper
• Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

  2013cites this paper
• Pharmacokinetics of Micafungin in Pediatric Patients With Invasive Candidiasis and Candidemia

  2012cites this paper
• Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood.

  2012cites this paper
• Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

  2012cites this paper
• Pharmacological Properties of Antifungal Drugs with a Focus on Anidulafungin

  2012cites this paper
• [Candidemia and invasive candidiasis in the adult: clinical forms and treatment].

  2012cites this paper
• Pharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia

  2012cites this paper
• [Factors affecting the pharmacokinetics after living donor liver transplant].

  2012cites this paper
• Pediatric Antifungal Drug Development: Lessons Learned and Recommendations for the Future

  2012cites this paper
• Echinocandin Antifungal Drugs in Fungal Infections

  2012cites this paper
• Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison

  2012cites this paper
• Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics

  2012cites this paper
• Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

  2012cites this paper
• Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations

  2012cites this paper
• Micafungin Review of its Use in the Prophylaxis and Treatment of

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions

  2012cites this paper
• Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins

  2012cites this paper
• Micafungin

  2012cites this paper
• Micafungin

  2012cites this paper
• Pharmacokinetics of Amphotericin B Colloidal Dispersion in Critically Ill Patients with Cholestatic Liver Disease

  2012cites this paper
• Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis

  2011cites this paper
• Effect of blood decrease on micafungin disposition in rats

  2011cites this paper
• First case report of acquired pure red cell aplasia associated with micafungin.

  2011cites this paper
• Enfermedades Infecciosas y Microbiología

  2011cites this paper
• Antifungal Therapy in Patients with Hematological Malignancies

  2011cites this paper